TCFL5 and Glucose intolerance: chα-IAPP-O reduced the progression of glucose intolerance and improved glucose-stimulated insulin secretion compared to vehicle after 8, 15, and 24 weeks of treatment with steady state plasma drug concentrations around 90 μg/ml (Fig. 4b, c and Supplementary Fig. 9a,b).